flurbiprofen + nalbuphine

Flurbiprofen + nalbuphine is a combination analgesic therapy consisting of two pharmacologically distinct agents. Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its effects primarily through inhibition of cyclooxygenase (COX), leading to reduced prostaglandin synthesis and thus decreased inflammation and pain. Nalbuphine is an opioid analgesic with mixed agonist-antagonist properties; it acts as an agonist at kappa opioid receptors and as an antagonist or partial agonist at mu opioid receptors, providing effective pain relief with a lower risk of certain opioid-related side effects such as respiratory depression. This combination has been studied for perioperative and postoperative pain management, including in elderly patients undergoing gastrointestinal surgery or patients experiencing remifentanil-induced hyperalgesia during laparoscopic procedures. The rationale for combining these drugs lies in their complementary mechanisms—NSAID-mediated reduction of inflammatory mediators alongside central modulation of pain by the opioid—potentially allowing for enhanced analgesia with reduced doses and minimized adverse effects[1][2][3][5][6].

Other names

flurbiprofen and nalbuphineflurbiprofen-axetil + nalbuphine